Discloses the use of an anti-human progastrin (hPG) antibody for the manufacture of a medicament for use in the treatment of pancreatic cancer, wherein the antibody specifically binds to human progastrin polypeptide having an amino acid sequence of SEQ ID NO: 101, but does not bind to an amidated gastrin 17, a glycine-extended gastrin 17 or the C-terminal flanking peptide (CTFP).